SENS•globenewswire•
Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
Summary
GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 29, 2026 by globenewswire